Related Experiment Video

Updated: Feb 18, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Immune checkpoints, their control by immunotherapy and ovarian cancer

Chinmoy K Bose1

  • 1NSC Bose Cancer Research Institute, Calcutta, India.

Contemporary Oncology (Poznan, Poland)
|November 29, 2017
PubMed

Insights

Immune checkpoints offer new strategies for controlling malignant tumors, particularly effective for recurrent and refractory cancers like melanoma, renal cell carcinoma, and ovarian cancer.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune checkpoints are crucial regulators of the immune system.
  • Dysregulation of immune checkpoints can lead to uncontrolled tumor growth.
  • Targeting immune checkpoints represents a promising approach in cancer immunotherapy.

Purpose of the Study:

  • To highlight the significance of immune checkpoints as therapeutic targets in oncology.
  • To discuss the application of immune checkpoint inhibitors in managing difficult-to-treat cancers.
  • To emphasize the rapid advancements and future directions in this field.

Main Methods:

  • Review of current literature on immune checkpoint inhibitors.
  • Analysis of clinical data for recurrent melanoma, renal cell carcinoma, and ovarian cancer.
  • Discussion of ongoing research and emerging strategies.

Main Results:

  • Immune checkpoints are effective in managing recurrent and refractory cancers.
  • Significant unmet needs exist in treating specific malignancies like ovarian cancer.
  • Rapid progress is being made, with multiple therapeutic avenues emerging.

Conclusions:

  • Immune checkpoint manipulation is a vital strategy for cancer treatment.
  • Further research is essential to overcome existing challenges and optimize therapies.
  • Ovarian cancer patients hold significant hope for advancements in immune checkpoint-based treatments.
Keywords:
T cellimmune checkpointovarian cancer

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K